Study of Olutasidenib and Temozolomide in HGG
Conditions: High Grade Glioma; Astrocytoma; Astrocytoma, Grade III; Astrocytoma, Grade IV; Diffuse Intrinsic Pontine Glioma; WHO Grade III Glioma; WHO Grade IV Glioma; Metastatic Brain Tumor; Diffuse Midline Glioma, H3 K27M-Mutant; Thalamus Tumor; Spinal Tumor; IDH1 Mutation; IDH1 R132; IDH1 R132C; IDH1 R132H; IDH1 R132S; IDH1 R132G; IDH1 R132L; Oligodendroglioma Interventions: Drug: Olutasidenib + TMZ Sponsors: Nationwide Children ' s Hospital; Rigel Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Human Induced Pluripotent Stem Cells Derived Natural Killer Cell(XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
Conditions: Glioblastoma; GBM Interventions: Biological: XS005 Cell Injection; Drug: Temozolomide （TMZ） Sponsors: Dushu Lake Hospital Affiliated to Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene.
Conditions: Glioblastoma Interventions: Drug: PLB1001; Drug: Temozolomide; Drug: Cisplatin combined with etoposide Sponsors: Beijing Pearl Biotechnology Limited Liability Company Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma.
Conditions: Glioblastoma, IDH-wildtype; MGMT-Methylated Glioblastoma Interventions: Drug: Regorafenib; Drug: Temozolomide Sponsors: Istituto Oncologico Veneto IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors Intervention: Drug: Surufatinib Combined With Temozolomide and S-1 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2023 Category: Research Source Type: clinical trials
